NCT04509323

Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

A Randomized, Controlled, Single-center Clinical Study of Huperzine A in the Treatment of Brain Injury in Patients With Hypertensive Cerebral Hemorrhage

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Jiangsu Famous Medical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage； 2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。

Detailed description

A randomized, controlled, single-center, exploratory clinical research method was used. In the treatment plan, the experimental group used basic treatment + Huperzine A, and the control group only used basic treatment, with a total of 20 cases. To evaluate the effectiveness and safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage.

Conditions

• Neurosensory Disorder

Interventions

Type	Name	Description
DRUG	Huperzine A for Injection	Give the patient one intramuscular injection (0.2mg) of Huperzine A of injection once a day for 14 days

Timeline

• Start date: 2020-08-03
• Primary completion: 2021-02-28
• Completion: 2021-05-28
• First posted: 2020-08-12
• Last updated: 2020-08-12

Locations

1 site across 1 country: China